Move to topTop
March 23, 2015

Leuven, Belgium - March 23, 2015

The AVROTROS television programme EenVandaag focuses today on possible residues of glue in injection needles. This would be the result of the use of epoxy glue to fix the metal needle onto the plastic hub of the needle. Epoxy glue is used frequently in the sector of medical devices.

Terumo has given explanation and provided the editors - in all transparency - with all relevant information concerning the production process. EenVandaag however, gives in its broadcast a biased presentation of the facts, and thus incorrectly creates a sense of anxiety with patients.

Epoxy glue is a type of glue that is used frequently in the sector of medical devices to fix the metal needle onto the plastic hub of the needle. It is a proven and widely used technique that has proven its usefulness. As the most of the producers of injection needles, Terumo also uses this technique.

Terumo Europe has, based on own research, found in 2012 that in a number of cases minuscule fluid glue parts do not harden and there is thus a chance that traces of fluid glue parts come into the body through the injection needle.

The product is BADGE (Bisphenol A dyglicidyl ether), which is not considered as CMR (carcinogen, mutagen or toxic for reproduction) by the European regulation. After these findings in 2012, we have launched an internal and external research. These analyses have proven that our injection needlesrepresent no health risk.

Injection needles that are produced by the use of epoxy glue, comply with all the norms and legal requirements. They pose, contrary to what is being insinuated by EenVandaag, hence no health risks to patients.

Patient safety is central to Terumo's activities. The company abides therefore the highest quality norms. The company has immediately taken all necessary measures to inform the Dutch and Belgian authorities.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.